X

Drug Profile

Monoclonal antibody HNK20

Alternative Names: Anti-RSV monoclonal antibody HNK20; HNK 20; MAb HNK20; Monoclonal IgA antibody HNK20

Latest Information Update: 23 Apr 2003

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Acambis
Class Antivirals; Monoclonal antibodies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Respiratory syncytial virus infections

Most Recent Events

11 Dec 2000 OraVax is now called Acambis
24 May 1999 OraVax acquired by Peptide Therapeutics
20 Jun 1997 Data have been added to the therapeutic trials and adverse event sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com